ARTICLE | Company News
ANDA filed for NaPro's paclitaxel
March 6, 2001 8:00 AM UTC
Abbott (ABT) and NPRO submitted an abbreviated NDA for NPRO's paclitaxel formulation to treat cancer. ABT has exclusive rights to market the compound in the U.S. and Canada (see BioCentury, July 3, 2...